“We have been working towards a multi-indication PBS listing for nivolumab and ipilimumab with the PBAC since 2017. We have maintained momentum throughout this period as we have always understood the importance and impact of expedited access for Australian patients,” said Owen Smith, General Manager of Bristol Myers Squibb Australia and New Zealand. …
PBS listing expands access to immunotherapy for Australians with advanced cancer
March 1, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Moderna expands support for early career Australian mRNA researchers
May 7, 2026 - - Latest News -
The review is formally over. Why is it restarting?
May 7, 2026 - - Latest News -
AI screening tool gives pathologists 'super' vision to detect hidden cancer
May 7, 2026 - - Latest News -
Australian company celebrated in centenary project on royal and parliamentary leadership
May 6, 2026 - - Latest News -
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News